

101.425-06 – including *Taq* polymerase  
 101.425-06u – without *Taq* polymerase

Visit [www.caredx.com](http://www.caredx.com) for  
 “Instructions for Use” (IFU)

Lot No.: **2R2**

Lot-specific information  
**Olerup SSP<sup>®</sup> HLA-A\*34**

<b>Product number:</b>	<b>101.425-06 – including <i>Taq</i> pol.</b> <b>101.425-06u – without <i>Taq</i> pol.</b>
<b>Lot number:</b>	<b>2R2</b>
<b>Expiry date:</b>	<b>2026-08-01</b>
<b>Number of tests:</b>	<b>6</b>
<b>Number of wells per test:</b>	<b>11+1</b>
<b>Storage - pre-aliquoted primers:</b>	<b>dark, between -15°C and -25°C</b>
- PCR Master Mix:	<b>between -15°C and -25°C</b>
- Adhesive PCR seals	<b>RT</b>

**This Product Description is only valid for Lot No. 2R2.**

Complete product documentation consists of generic Instructions for Use (IFU), lot specific Product Insert, Worksheet and Certificate.

**CHANGES COMPARED TO THE PREVIOUS OLERUP SSP<sup>®</sup>  
 HLA-A\*34 LOT (1H6)**

- The product documentation has been updated for new alleles of IMGT 3.49.0.
- The kit resolution focuses on common and well documented (CWD) alleles<sup>1</sup>.

<sup>1</sup>As described in section Uniquely Identified Alleles.

The HLA-A\*34 specificity and interpretation tables have been updated for the HLA-A alleles described since the previous *Olerup SSP<sup>®</sup> HLA-A\*34* lot was made (**Lot No. 1H6**).

The HLA-A\*34 primer set is unchanged compared to the previous *Olerup SSP<sup>®</sup> HLA-A\*34* (**Lot No. 1H6**).



**0197**

101.425-06 – including *Taq* polymerase

101.425-06u – without *Taq* polymerase

Visit [www.caredx.com](http://www.caredx.com) for  
“Instructions for Use” (IFU)

Lot No.: **2R2**

Lot-specific information

Well **12** contains Negative Control primer pairs, that will amplify the majority of the *Olerup* SSP<sup>®</sup> HLA Class I, DRB, DQB1, DPB1 and DQA1 amplicons as well as all the amplicons generated by the control primer pairs matching the human growth hormone gene.

HLA-specific PCR product sizes range from 75 to 200 base pairs.

The PCR product generated by the positive control primer pair is 200 base pairs.

Length of PCR product	105	200	105	80	75	80	85
<b>5'-primer<sup>1</sup></b>	<b>164</b>	<b>340</b>	<b>440</b>	<b>45</b>	<b>45</b>	<b>43</b>	<b>36</b>
	5'-CAC <sup>3'</sup>	5'-Agg <sup>3'</sup>	5'-TTA <sup>3'</sup>	5'-Tgg <sup>3'</sup>	5'-Tgg <sup>3'</sup>	5'-Tgg <sup>3'</sup>	5'-TAC <sup>3'</sup>
							<b>36</b>
							5'-TAT <sup>3'</sup>
<b>3'-primer<sup>2</sup></b>	<b>231</b>	<b>2<sup>nd</sup> I</b>	<b>507</b>	<b>59</b>	<b>58</b>	<b>57</b>	<b>47</b>
	5'-TgC <sup>3'</sup>	5'-AAA <sup>3'</sup>	5'-TTg <sup>3'</sup>	5'-CTC <sup>3'</sup>	5'-ggC <sup>3'</sup>	5'-CTC <sup>3'</sup>	5'-ACA <sup>3'</sup>
							<b>48</b>
							5'-gCA <sup>3'</sup>
							<b>48</b>
							5'-gCC <sup>3'</sup>
							<b>52</b>
							5'-TgT <sup>3'</sup>
<b>A*</b>	<b>+</b>	<b>+</b>	<b>+</b>				
<b>B*</b>	<b>+</b>	<b>+</b>	<b>+</b>				
<b>C*</b>	<b>+</b>	<b>+</b>	<b>+</b>				
<b>DRB1</b>				<b>+</b>	<b>+</b>		
<b>DRB3</b>				<b>+</b>	<b>+</b>		
<b>DRB5</b>				<b>+</b>			
<b>DQB1</b>					<b>+</b>		
<b>DPB1</b>						<b>+</b>	
<b>DQA1</b>							<b>+</b>

<sup>1</sup>The nucleotide position for HLA class I genes and the codon for HLA class II genes, in the 2<sup>nd</sup> or 3<sup>rd</sup> exon, matching the specificity-determining 3'-end of the primer is given. Nucleotide and codon numbering as on the [www.ebi.ac.uk/imgt/hla](http://www.ebi.ac.uk/imgt/hla) web site. The sequence of the 3 terminal nucleotides of the primer is given.

<sup>2</sup>The nucleotide position for HLA class I genes and the codon for HLA class II genes, in the 2<sup>nd</sup> or 3<sup>rd</sup> exon or the 2<sup>nd</sup> intron, matching the specificity-determining 3'-end of the primer is given in the anti-sense direction. Nucleotide and codon numbering as on the [www.ebi.ac.uk/imgt/hla](http://www.ebi.ac.uk/imgt/hla) web site. The sequence of the 3 terminal nucleotides of the primer is given.



0197

For *In Vitro* Diagnostic Use  
MA123 v02 SSP PI Template  
Date: August 2022, Rev. No: 00

101.425-06 – including *Taq* polymerase  
 101.425-06u – without *Taq* polymerase

Visit [www.caredx.com](http://www.caredx.com) for  
 “Instructions for Use” (IFU)

Lot No.: **2R2**

Lot-specific information  
**PRODUCT DESCRIPTION**

**HLA-A\*34 SSP subtyping**

**CONTENT**

The primer set contains 5'- and 3'-primers for identifying the A\*34:01 to A\*34:30N alleles.

**PLATE LAYOUT**

Each test consists of 12 PCR reactions in a 16 well cut PCR plate. Wells 13 to 16 are empty.

<b>1</b>	<b>2</b>	<b>3</b>	<b>4</b>	<b>5</b>	<b>6</b>	<b>7</b>	<b>8</b>
<b>9</b>	<b>10</b>	<b>11</b>	<b>NC</b>	empty	empty	empty	empty

The 16 well cut PCR plate is marked with ‘HLA-A\*34’ in silver/gray ink.

Well No. 1 is marked with the Lot No. ‘2R2’.

Wells 1 to 11 – HLA-A\*34 high resolution primers.

Well 12 – Negative Control (NC).

A faint row of numbers is seen between wells 1 and 2 or wells 7 and 8 of the PCR trays. These stem from the manufacture of the trays, and should be disregarded. The PCR plates are heat-sealed with a PCR-compatible foil.

**Please note:** When removing each 16 well PCR plate, make sure that the remaining plates stay sealed. Use a scalpel or a similar instrument to carefully cut the foil between the plates.

**INTERPRETATION**

Due to the sharing of sequence motifs between HLA-A alleles non-HLA-A\*34 alleles will be amplified by some primer mixes. For further details see Specificity Table.

**UNIQUELY IDENTIFIED ALLELES**

All the HLA-A\*34 alleles, i.e. **A\*34:01 to A\*34:30N alleles**, recognized by the HLA Nomenclature Committee in July 2022<sup>1,2</sup> will be amplified by the primers in the HLA-A\*34 subtyping kit.

The HLA-A\*34 kit enables separation of the confirmed HLA-A\*34 alleles as listed in the IMGT/HLA database 3.33.0. An HLA allele is listed as confirmed by IMGT/HLA if it has been sequenced by more than a single laboratory or from multiple sources. Current allele confirmation status for HLA-A\*34 alleles is listed below.

The HLA-A\*34 kit also enables identification of many null and alternatively expressed alleles.



**0197**

101.425-06 – including *Taq* polymerase  
 101.425-06u – without *Taq* polymerase

Visit [www.caredx.com](http://www.caredx.com) for  
 “Instructions for Use” (IFU)

Lot No.: **2R2**

**Lot-specific information**

<sup>1</sup>HLA-A alleles listed on the IMGT/HLA web page 2022-July-13, release 3.49.0, [www.ebi.ac.uk/imgt/hla](http://www.ebi.ac.uk/imgt/hla).

<sup>2</sup>Alleles that have been deleted from or renamed in the official WHO HLA Nomenclature up to and including the last IMGT/HLA database release can be retrieved from web page <http://hla.alleles.org/alleles/deleted.html>.

**ALLELE CONFIRMATION STATUS**

Allele	Status <sup>1</sup>	Allele	Status <sup>1</sup>	Allele	Status <sup>1</sup>
A*34:01:01:01	Confirmed	A*34:06	Unconfirmed	A*34:16	Unconfirmed
A*34:01:01:02	Unconfirmed	A*34:07	Unconfirmed	A*34:17	Unconfirmed
A*34:01:02	Unconfirmed	<b>A*34:08</b>	<b>Confirmed</b>		
<b>A*34:02:01</b>	<b>Confirmed</b>	A*34:09	Unconfirmed		
A*34:02:02	Unconfirmed	A*34:10N	Unconfirmed		
<b>A*34:02:03</b>	<b>Confirmed</b>	A*34:11	Unconfirmed		
A*34:02:04	Unconfirmed	A*34:12	Unconfirmed		
<b>A*34:03</b>	<b>Confirmed</b>	A*34:13	Unconfirmed		
A*34:04	Unconfirmed	A*34:14	Unconfirmed		
<b>A*34:05</b>	<b>Confirmed</b>	A*34:15	Unconfirmed		

<sup>1</sup>Allele status “confirmed” or “unconfirmed” as listed on the IMGT/HLA web page 2018-July-11, release 3.33.0, [www.ebi.ac.uk/imgt/hla](http://www.ebi.ac.uk/imgt/hla).

**RESOLUTION IN HOMO- AND HETEROZYGOTES**

Results file with resolution in HLA-A\*34 homo- and heterozygotes is available upon request.



0197

101.425-06 – including *Taq* polymerase  
 101.425-06u – without *Taq* polymerase

Visit [www.caredx.com](http://www.caredx.com) for  
 “Instructions for Use” (IFU)

Lot No.: **2R2**

Lot-specific information  
**SPECIFICITY TABLE**

**HLA-A\*34 SSP subtyping**

**Specificities and sizes of the PCR products of the 11+1 primer mixes used for HLA-A\*34 SSP subtyping**

Primer Mix	Size of spec. PCR product <sup>1</sup>	Size of control band <sup>2</sup>	Amplified HLA-A*34 alleles <sup>3</sup>	Other amplified HLA Class I alleles
<b>1<sup>4</sup></b>	100 bp	<b>800 bp</b>	*34:01:01:01-34:06, 34:08, 34:10N-34:30N	*01:13, 01:17, 01:176, 01:302, 02:741, 03:63, 03:88, 03:382, 11:01:01:01-11:01:67, 11:01:69-11:01:72, 11:01:74-11:01:75, 11:01:77-11:11, 11:13-11:16, 11:20-11:27, 11:29-11:39, 11:41-11:52Q, 11:54:01-11:95, 11:97, 11:99N-11:105, 11:107-11:120, 11:122-11:158, 11:160-11:177, 11:179-11:249, 11:251N-11:290, 11:292-11:300, 11:302:01-11:307, 11:309-11:311, 11:313Q-11:324, 11:326-11:398, 11:400N-11:428, 25:02, 25:75, 26:13, 26:19, 26:33, 29:66, 30:125, 30:140, 66:01:01:01-66:01:07, 66:04, 66:06-66:11, 66:13-66:14, 66:17-66:20, 66:22-66:24, 66:27N, 66:29-66:33, 66:35-66:38, 66:40-66:42, 66:44-66:46, 68:227, 69:02, <b>C*07:335</b>
<b>2<sup>4</sup></b>	110 bp	1070 bp	*34:01:01:01-34:01:07, 34:05, 34:11-34:12, 34:14, 34:16-34:18, 34:23, 34:27	*02:741, 26:48, 26:69
<b>3</b>	195 bp	1070 bp	*34:02:01:01-34:02:07, 34:04, 34:07-34:10N, 34:13, 34:15, 34:20-34:21, 34:24-34:26N, 34:28-34:30N	*03:248, 11:191, 11:404, 25:43
<b>4<sup>6</sup></b>	135 bp	<b>800 bp</b>	*34:03, 34:06, 34:17	*03:01:19, 03:103:02, 25:09, 26:14, 26:18, 26:28, 26:73, 26:112:01-26:112:02, 26:146, 31:03-31:04:02, 31:123, 66:22, 66:43, 74:01:03
<b>5</b>	200 bp	<b>800 bp</b>	*34:04	*01:226, 11:257, 26:198, 31:01:07, 32:128, <b>B*15:82, B*15:260, B*40:186:01, C*03:186:01, C*04:344, C*12:57:02</b>



0197

101.425-06 – including *Taq* polymerase  
 101.425-06u – without *Taq* polymerase

Visit [www.caredx.com](http://www.caredx.com) for  
 “Instructions for Use” (IFU)

Lot No.: **2R2**

Lot-specific information

Lot No.: <b>2R2</b>		Lot-specific information		
<b>6</b>	155 bp	1070 bp	*34:05	*02:91, 02:322, 03:94, 68:239, <b>C*05:149, C*07:81, C*07:243, C*07:878, C*15:161, C*16:76</b>
<b>7<sup>7</sup></b>	140 bp	1070 bp	*34:06	*26:18, 26:112:01 <sup>w</sup> , 26:112:02, 31:03-31:04:02, 31:123, 66:43, 74:01:03
<b>8<sup>5</sup></b>	215 bp		*34:07	*11:96
	200 bp	<b>800 bp</b>	*34:08	*01:51, 02:55, 02:644, 02:741, 02:815, 03:24, 25:03, 25:30, 26:20:01-26:20:02, 32:15, 68:71, 69:07
	360 bp		*34:09	*02:135, 02:309, 02:454, 03:01:19, 03:103:02, 25:13, 25:82, 26:30, 26:65, 31:04:01:01- 31:04:02, 31:123, 66:02:01:01- 66:03:01:03, 66:12, 66:16, 66:21, 66:25-66:26Q, 66:28N, 66:34, 66:39N, 66:43, 68:294, 74:01:03
<b>9</b>	175 bp	1070 bp	*34:11	
<b>10</b>	185 bp	1070 bp	*34:10N	
<b>11</b>	175 bp	1070 bp	*34:01:01:01-34:09, 34:12-34:30N	*02:309, 02:454, 03:01:19, 03:103:02, 25:06, 26:09, 26:91, 31:03-31:04:02, 31:123, 68:294, 74:01:03
<b>12<sup>8</sup></b>	<b>Negative Control</b>			

<sup>1</sup>Alleles are assigned by the presence of specific PCR product(s). However, the sizes of the specific PCR products may be helpful in the interpretation of HLA-A\*34 SSP typings. When the primers in a primer mix can give rise to HLA-specific PCR products of more than one length this is indicated if the size difference is more than 20 base pairs. Size differences of 20 base pairs or less are not given. For high resolution SSP kits, the alleles listed are specified according to amplicon length.

Nonspecific amplifications, i.e. a ladder or a smear of bands, may sometimes be seen. GC-rich primers have a higher tendency of giving rise to nonspecific amplifications than other primers. PCR fragments longer than the control bands may sometimes be observed. Such bands should be disregarded and do not influence the interpretation of the SSP typings.

PCR fragments migrating faster than the control bands, but slower than a 400 bp fragment may be seen in some gel read-outs. Such bands can be disregarded and do not influence the interpretation of the SSP typings.

Some primers may give rise to primer oligomer artifacts. Sometimes this phenomenon is an inherent feature of the primer pair(s) of a primer mix. More often it is due to other factors such as too low amount of DNA in the PCR reactions, taking too long time in setting up the PCR reactions, working at elevated room temperature or using thermal cyclers that are not pre-heated.

<sup>2</sup>The internal positive control primer pairs amplify segments of the human growth hormone gene. The internal positive control bands are 1070 or 800 base pairs respectively, well distribution as outlined in the table. Well number 1 contains the shorter, 800 bp, internal positive control band. The well distribution of the internal controls can help in orientation of the kit on gel photo, as well as allow for kit identification. In the presence of a specific amplification the intensity of the control band often decreases.

<sup>3</sup>For several HLA Class I alleles 1<sup>st</sup> and/or 4<sup>th</sup> exon(s) and beyond, as well as intron nucleotide sequences, are not available. In these instances it is not known whether some of the primers of the SSP sets are completely matched with the target sequences or not. Assumption is made that unknown sequences in these regions are conserved within allelic groups.



0197

101.425-06 – including *Taq* polymerase  
 101.425-06u – without *Taq* polymerase

Visit [www.caredx.com](http://www.caredx.com) for  
 “Instructions for Use” (IFU)

**Lot No.: 2R2**

**Lot-specific information**

<sup>4</sup>HLA-specific PCR products shorter than 125 base pairs have a lower intensity and are less sharp than longer PCR products.

<sup>5</sup>In primer mix 8 the positive control band may be weaker than for other HLA-A\*34 primer mixes.

<sup>6</sup>Primer mix 4 may have tendencies of unspecific amplification.

<sup>7</sup>Primer mix 7 may give rise to a long fragment of approx. 700 bp in some HLA-A alleles. This band should not be considered in the interpretation of HLA-A\*34 typings.

<sup>8</sup>Primer mix 12 contains a negative control, which will amplify the majority of HLA amplicons as well as the amplicons generated by the control primer pairs matching the human growth hormone gene. HLA-specific PCR product sizes range from 75 to 200 base pairs and the PCR product generated by the HGH positive control primer pair is 200 base pairs.

Abbreviations

'w', might be weakly amplified.



0197

For *In Vitro* Diagnostic Use  
 MA123 v02 SSP PI Template  
 Date: August 2022, Rev. No: 00

101.425-06 – including *Taq* polymerase  
 101.425-06u – without *Taq* polymerase

Visit [www.caredx.com](http://www.caredx.com) for  
 “Instructions for Use” (IFU)

Lot No.: **2R2**

Lot-specific information  
**PRIMER SPECIFICATION**

Well No.	1	2	3	4	5	6	7	8	9	10	11
Length of spec. PCR product	100	110	195	135	200	155	140	200	175	185	175
							215	360			
Length of int. pos. control <sup>1</sup>	800	1070	1070	800	800	1070	1070	800	1070	1070	1070
5'-primer(s) <sup>2</sup>	282	270	363	423	78	445	103	102	423	415	423
	5'-CAg 3'	5'-AAA 3'	5'-ATA 3'	5'-gCT 3'	5'-TCC 3'	5'-TCT 3'	5'-CCT 3'	5'-ACA 3'	5'-gCT 3'	5'-ggT 3'	5'-gCT 3'
							423	341			
							5'-gCT 3'	5'-ggC 3'			
3'-primer(s) <sup>3</sup>	341	341	517	517	238	559	277	259	559	559	559
	5'-CgT 3'	5'-CgT 3'	5'-CgT 3'	5'-CgC 3'	5'-CCT 3'	5'-CgT 3'	5'-ggA 3'	5'-gTT 3'	5'-CgC 3'	5'-CgT 3'	5'-CgT 3'
							524	418			
							5'-CAC 3'	5'-gTC 3'			
Well No.	1	2	3	4	5	6	7	8	9	10	11

<sup>1</sup>The internal positive control primer pairs amplify segments of the human growth hormone gene. The internal positive control bands are 1070 or 800 base pairs respectively, well distribution as outlined in the table. Well number 1 contains the shorter, 800 bp, internal positive control band. The well distribution of the internal controls can help in orientation of the kit on gel photo, as well as allow for kit identification. In the presence of a specific amplification the intensity of the control band often decreases.

<sup>2</sup>The nucleotide position matching the specificity-determining 3'-end of the primer is given. Nucleotide numbering as on the [www.ebi.ac.uk/imgt/hla](http://www.ebi.ac.uk/imgt/hla) web site. The sequence of the 3 terminal nucleotides of the primer is given.

<sup>3</sup>The nucleotide position matching the specificity-determining 3'-end of the primer is given in the anti-sense direction. Nucleotide numbering as on the [www.ebi.ac.uk/imgt/hla](http://www.ebi.ac.uk/imgt/hla) web site. The sequence of the 3 terminal nucleotides of the primer is given.



0197



101.425-06 – including Taq polymerase  
 101.425-06u – without Taq polymerase

Visit [www.caredx.com](http://www.caredx.com) for  
 “Instructions for Use” (IFU)

Lot No.: **2R2**

Lot-specific information

CELL LINE VALIDATION SHEET																
HLA-A*34 SSP subtyping kit <sup>2</sup>																
					Well											
					1	2	3	4	5	6	7	8	9	10	11	
					Prod No.:	202243201	202243202	202243203	202243204	202243205	202243206	202243207	202243208	202243209	202243210	202243211
	IHWC cell line <sup>1</sup>	A*	A*													
1	9001 SA	*24:02			-	-	-	-	-	-	-	-	-	-	-	-
2	9280 LK707	*02:01			-	-	-	-	-	-	-	-	-	-	-	-
3	9011 E4181324	*01:01			-	-	-	-	-	-	-	-	-	-	-	-
4	9275 GU373	*30:01			-	-	-	-	-	-	-	-	-	-	-	-
5	9009 KAS011	*01:01			-	-	-	-	-	-	-	-	-	-	-	-
6	9353 SM	*02:01	*26:03		-	-	-	-	-	-	-	-	-	-	-	-
7	9020 QBL	*26:01			-	-	-	-	-	-	-	-	-	-	-	-
8	9025 DEU	*31:01			-	-	-	-	-	-	-	-	-	-	-	-
9	9026 YAR	*26:01			-	-	-	-	-	-	-	-	-	-	-	-
10	9107 LKT3	*24:02			-	-	-	-	-	-	-	-	-	-	-	-
11	9051 PITOUT	*29:02			-	-	-	-	-	-	-	-	-	-	-	-
12	9052 DBB	*02:01			-	-	-	-	-	-	-	-	-	-	-	-
13	9004 JESTHOM	*02:01			-	-	-	-	-	-	-	-	-	-	-	-
14	9071 OLGA	*31:01			-	-	-	-	-	-	-	-	-	-	-	-
15	9075 DKB	*24:02			-	-	-	-	-	-	-	-	-	-	-	-
16	9037 SWEIG007	*29:02			-	-	-	-	-	-	-	-	-	-	-	-
17	9282 CTM3953540	*03:01	*80:01		-	-	-	-	-	-	-	-	-	-	-	-
18	9257 32367	*33:03	*74:01		-	-	-	-	-	-	-	-	-	-	-	-
19	9038 BM16	*02:01			-	-	-	-	-	-	-	-	-	-	-	-
20	9059 SLE005	*02:01			-	-	-	-	-	-	-	-	-	-	-	-
21	9064 AMALA	*02:17			-	-	-	-	-	-	-	-	-	-	-	-
22	9056 KOSE	*02:01			-	-	-	-	-	-	-	-	-	-	-	-
23	9124 IHL	*02:01	*34:01		+	+	-	-	-	-	-	-	-	-	-	+
24	9035 JBUSH	*32:01			-	-	-	-	-	-	-	-	-	-	-	-
25	9049 IBW9	*33:01			-	-	-	-	-	-	-	-	-	-	-	-
26	9285 WT49	*02:05			-	-	-	-	-	-	-	-	-	-	-	-
27	9191 CH1007	*24:10	*29:01		-	-	-	-	-	-	-	-	-	-	-	-
28	9320 BEL5GB	*02:01	*29:02		-	-	-	-	-	-	-	-	-	-	-	-
29	9050 MOU	*29:02			-	-	-	-	-	-	-	-	-	-	-	-
30	9021 RSH	*30:01	*68:02		-	-	-	-	-	-	-	-	-	-	-	-
31	9019 DUCAF	*30:02			-	-	-	-	-	-	-	-	-	-	-	-
32	9297 HAG	*02:01			-	-	-	-	-	-	-	-	-	-	-	-
33	9098 MT14B	*31:01			-	-	-	-	-	-	-	-	-	-	-	-
34	9104 DHIF	*31:01			-	-	-	-	-	-	-	-	-	-	-	-
35	9302 SSTO	*32:01			-	-	-	-	-	-	-	-	-	-	-	-
36	9024 KT17	*02:06	*11:01		+	-	-	-	-	-	-	-	-	-	-	-
37	9065 HHKB	*03:01			-	-	-	-	-	-	-	-	-	-	-	-
38	9099 LZL	*02:17			-	-	-	-	-	-	-	-	-	-	-	-
39	9315 CML	*01:01	*03:01		-	-	-	-	-	-	-	-	-	-	-	-
40	9134 WHONP199	*02:07	*30:01		-	-	-	-	-	-	-	-	-	-	-	-
41	9055 H0301	*03:01			-	-	-	-	-	-	-	-	-	-	-	-
42	9066 TAB089	*02:07			-	-	-	-	-	-	-	-	-	-	-	-
43	9076 T7526	*02:06	*02:07		-	-	-	-	-	-	-	-	-	-	-	-
44	9057 TEM	*66:01			+	-	-	-	-	-	-	-	-	-	-	-
45	9239 SHJO	*23:01	*24:02		-	-	-	-	-	-	-	-	-	-	-	-
46	9013 SCHU	*03:01			-	-	-	-	-	-	-	-	-	-	-	-
47	9045 TUBO	*02:16	*03:01		-	-	-	-	-	-	-	-	-	-	-	-
48	9303 TER-ND	*02:01	*11:01		+	-	-	-	-	-	-	-	-	-	-	-



0197

101.425-06 – including *Taq* polymerase  
 101.425-06u – without *Taq* polymerase

Visit [www.caredx.com](http://www.caredx.com) for  
 “Instructions for Use” (IFU)

**Lot No.: 2R2**

**Lot-specific information**

<sup>1</sup>The provided cell line HLA specificities are retrieved from the <http://www.ihwg.org/hla> web site. The specificity of an individual cell line may thus be subject to change.

<sup>2</sup>The specificity of each primer solution in the kit has been tested against 48 well characterized cell line DNAs and where applicable, additional cell line DNAs.

No DNAs carrying the alleles to be amplified by primer solutions 4, 5, 7, 9 and 10 were available. The specificities of the primers in primer solutions 4 and 7 were tested by separately adding one additional 5'-primer, respectively three additional 3'-primers. In primer solutions 5 and 9 it was only possible to test the 5'-primers, the 3-primers were not possible to test. In primer solution 10 it was only possible to test the 3'-primer, the 5-primer was not possible to test. In primer solution 7 one of the 3'-primers was not possible to test. One additional 5'-primer and one additional 3'-primer in primer mix 8 were tested by separately adding one additional 3'-primer or 5'-primer.



**0197**

For *In Vitro* Diagnostic Use  
 MA123 v02 SSP PI Template  
 Date: August 2022, Rev. No: 00

101.425-06 – including *Taq* polymerase  
 101.425-06u – without *Taq* polymerase

Visit [www.caredx.com](http://www.caredx.com) for  
 “Instructions for Use” (IFU)

Lot No.: **2R2**

Lot-specific information

**ADDRESSES:**

**Manufacturer:**

**CareDx AB**, Franzengatan 5, SE-112 51 Stockholm, Sweden.

Tel: +46-8-508 939 00

**Fax:** +46-8-717 88 18

**E-mail:** [orders-se@caredx.com](mailto:orders-se@caredx.com)

**Web page:** [www.caredx.com](http://www.caredx.com)

**Distributed by:**

**CareDx Lab Solutions Inc.**, 901 S. Bolmar St., Suite R, West Chester, PA 19382

**Tel:** 1-877-653-78171

**Fax:** 610-344-7989

**E-mail:** [orders-us@caredx.com](mailto:orders-us@caredx.com)

**Web page:** [www.caredx.com](http://www.caredx.com)

For information on CareDx distributors worldwide, contact **CareDx AB**.



0197

For *In Vitro* Diagnostic Use

MA123 v02 SSP PI Template

Date: August 2022, Rev. No: 00